Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2026)

Protalix BioTherapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 34.04% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 34.04% YoY), while the FY2025 annual figure was $15.6 million, up 3.47% from the prior year.
• Short-term Investments was $10.1 million for Q1 2026 at Protalix BioTherapeutics, down from $15.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $21.6 million in Q2 2024 to a low of $5.1 million in Q4 2022.
• Historically, Short-term Investments has averaged $15.6 million across 5 years, with a median of $15.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments plunged 73.46% in 2022, then soared 312.82% in 2023.
• A 5-year view of Short-term Investments shows it stood at $5.1 million in 2022, then soared by 312.82% to $20.9 million in 2023, then decreased by 27.98% to $15.1 million in 2024, then gained by 3.47% to $15.6 million in 2025, then sank by 35.34% to $10.1 million in 2026.
• The last three Short-term Investments figures came in at $10.1 million (Q1 2026), $15.6 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.